Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

Stock Information for Omeros Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Omeros Corporation

Omeros Corporation Reports First Quarter 2025 Financial Results
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025
 Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026
FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program
Omeros Corporation To Introduce Its Proprietary T-CAT(TM) Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases
Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.